Stroke

A stroke happens when interrupted blood flow or bleeding damages part of the brain. Its effects can continue after the initial emergency has passed. Post-stroke syndrome is a broad term for the ongoing physical, cognitive, emotional, and sensory changes a person may experience during recovery. Recovery looks different for every person. It depends on the type and location of the stroke, the extent of injury, other health conditions, and access to rehabilitation and follow-up care.

Common Post-Stroke Effects

Call emergency services immediately for new or worsening stroke symptoms, including sudden weakness or numbness, facial drooping, trouble speaking, severe headache, vision loss, dizziness, or loss of balance.

Stroke recovery involves more than one type of care. Treatment focuses on preventing another stroke, managing medical conditions that increase risk, treating complications, and helping each person regain as much function and independence as possible.

Standard Treatment Categories

• Stroke prevention: Blood-pressure management, cholesterol treatment, diabetes care, smoking cessation, and medicines such as antiplatelet or anticoagulant therapy may be used when appropriate.
• Rehabilitation: Physical, occupational, and speech-language therapy can help people work on mobility, self-care, communication, swallowing, and cognitive skills.
• Management of complications: Care may address spasticity, pain, depression, sleep problems, falls, or swallowing concerns.
• Ongoing follow-up: Primary care, neurology, rehabilitation medicine, and other specialists may help coordinate long-term recovery and risk reduction.
• Support for patients and families: Caregiver support, mental-health services, assistive technology, and community-based programs can be valuable parts of recovery.

Stem cell therapy for stroke recovery is being studied because cell-based approaches may influence inflammation and the environment around injured brain tissue after ischemic stroke. Researchers are evaluating different cell products, doses, delivery methods, and treatment time frames. This work is contributing to the broader study of regenerative medicine for stroke recovery.

What Researchers Are Studying

• Influence inflammatory and immune-system signaling after stroke
• Affect the environment around injured brain tissue
• Be delivered safely and feasibly in carefully selected patients
• Be further evaluated for their effects on motor, cognitive, or functional recovery

Some studies use intravenous cell infusion in the first days or weeks after stroke, while others examine different cell sources or more direct delivery methods. These approaches are distinct and continue to be studied separately.

Note: Stem cell therapies for stroke recovery are not FDA-approved and are investigational. Research findings do not guarantee individual results.

How Stem Cell Therapy for Stroke Is Being Studied

Researchers are evaluating possible effects on inflammation, immune signaling, and brain-recovery processes. Studies examine different cell products, delivery time frames, and outcomes related to movement, daily function, cognition, and quality of life. This work is helping identify the approaches and patient groups that warrant continued clinical study. Stem cell treatment for stroke remains investigational.

2021: UC-MSC Infusions Reported Improvement in an Acute Stroke Case Report

Treatment of Acute Ischemic Stroke by Minimally Manipulated Umbilical Cord-Derived Mesenchymal Stem Cells Transplantation: A Case Report — Read Study

This report described a 55-year-old man who received two intravenous infusions of minimally manipulated umbilical-cord-derived MSCs after an acute ischemic stroke. The authors reported improvement over follow-up and no adverse reactions in that individual. This report adds early clinical information on intravenous UC-MSC administration after acute ischemic stroke.

2017: Multipotent Adult Progenitor Cells Were Well Tolerated in Acute Ischemic Stroke

Safety and Efficacy of Multipotent Adult Progenitor Cells in Acute Ischaemic Stroke (MASTERS): A Randomised, Double-Blind, Placebo-Controlled, Phase II Trial — Read Study

This multicenter phase II trial randomized 129 people with moderately severe acute ischemic stroke to intravenous multipotent adult progenitor cells or placebo. The intention-to-treat analysis included 65 participants in the cell-treatment group and 61 in the placebo group. The investigators reported no dose-limiting toxicities or significant differences in treatment-emergent adverse events through 90 days. These findings add to clinical research on intravenous cell therapy in the first days after ischemic stroke.

2014: Autologous Bone-Marrow Cell Infusion Was Studied in Subacute Ischemic Stroke

Intravenous Autologous Bone Marrow Mononuclear Stem Cell Therapy for Ischemic Stroke: A Multicentric, Randomized Trial — Read Study

This multicenter randomized trial included 120 people with subacute ischemic stroke. Participants received either an infusion of their own bone-marrow mononuclear cells or standard care. The researchers evaluated independence, neurologic function, infarct volume, and adverse events through 180 days. The study provides comparative clinical information on intravenous autologous bone-marrow cell infusion after ischemic stroke.